Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis

Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...
TMCnet

BostonGene RNA Transcriptome Profiling Reveals New ADC Targets in Advanced Solid Tumors

BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...
Business Wire

Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...
Business Wire

Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ ...
Phys.org

Mining the dark transcriptome: Synthesizing the first potential drug molecules from long noncoding RNA

A team from University of Toronto Engineering is the first to synthesize long noncoding RNA (lncRNA) outside the cell—a new approach to drug discovery that has already yielded some promising ...
ascopubs.org

Clinical utility of comprehensive transcriptome testing in advanced solid tumors.

Evaluation of 68Ga-FAPI PET/CT and 18F-FDG PET/CT for the primary staging of non-small cell lung cancer (NSCLC). Application of an epigenomic-based classifier to identify cancer signal of origin on ...